Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 15-95 

High dose EC x 3 supported by PBSC vs. EC/AC x 4 followed by CMF as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (less than 65 years) patients

DESIGN

Design Trial 15-95

Results & Publications


Presentations


Publications

Study Chairs
Dr. Russel Basser - Melbourne, Australia
Prof. Monica Castiglione - Bern, Switzerland

Statistician
Anne O'Neill

Trial Coordinator
Holly Shaw

Data Managers
Tara Scolese, Dawn Weinbaum

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097

Email: ibcsg10-15@fstrf.org

Date of Activation
July 1995

Date of Closure
March 15, 2000

Targeted Accrual
300 patients

Final Accrual
344 patients


Results Publications Results & Publications
Other Pathology


News

21.05.2013:
A few impressions from our audits

10.04.2013:
New publications are available

19.03.2013:
The next  IBCSG Annual Meeting will take place in Glasgow, Scotland on March 21nd and 22th, 2014.

All News

 
  Print